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The road to Stockholm: from 2-4D to kuru prions 
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In 1939 at the Boyce Thompson Institute in Yonkers, New York, a 16-year-old high 
school student was hired as a summer helper by a plant physiologist, Percy 
Zimmerman. The helper, who was paid 40 cents/hour, successfully synthesized 2 – 
4D, described in Chemical Abstracts as a possible cure for athlete’s foot. There was 
no record made of the name of the summer helper, who left after four weeks and was 
forgotten. Zimmerman applied 2 – 4D to broad-leafed plants. They grew so rapidly 
that they collapsed and died. The first weed killer was thus discovered. It was 
patented by Zimmerman and the license sold to Dupont Co. in Wilmington, D.E. 
When I visited Zimmerman in 1954, I inquired how he got the idea of using 2 – 4D. 
When he mentioned the forgotten summer helper, I decided to search and find what 
happened to this bright student. It took me many years, before Irene Dobroscky, a 
former associate of my mentor L.O. Kunkel, visited me at Rockefeller University and 
told me that the summer helper of Zimmerman was her nephew, the famous virologist 
D. Carleton Gajdusek. In 1970, I met Gajdusek and when I greeted him as “the 
discoverer of 2 – 4D”, he thought that I confused him with someone else. I reminded 
him of his first employment at the Boyce Thompson Institute. He requested that I 
send him the names of the scientists who worked there in 1939.We became close 
friends. In 1976, when Gajdusek received the Nobel Prize in Stockholm, he told about 
his aunt and his synthesizing of 2 – 4D, of which I had reminded him a few years 
earlier. 
Gajdusek received his Nobel Prize for the discovery of the infectious agent causing 
the kuru disease of fore people in the highlands of New Guinea. Although 
cannibalism was banned there years earlier, brains of deceased fore family members 
were smeared on the faces of women and children, then cooked, and eaten. Gajdusek 
send sampled of kuru brains to his laboratory at the National Institutes of Health in 
the United States. After two years, chimpanzees inoculated with kuru brain extracts 
developed signs closely resembling human kuru. The disease in people and 
chimpanzees is always fatal. Gajdusek called the infectious agent a “slow virus”, 
resembling the infectious agents of Creutzfeldt-Jacob human dementia and scrapie of 
sheep. In 1974 Stanley Prusiner started to work with scrapie of sheep and found that 
“slow viruses” contain neither DNA nor RNA and consist of self-duplicating, twisted 
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protein. Using the first letters of his name, he coined the word “prion” for “slow 
viruses”. Prusiner won the Wolf Prize in 1996 and the Nobel Prize in 1997. 
Gajdusek brought the first New Guinea aborigines to the United States. One, of the 
Anga tribe, arrived barefoot, with a stick through his nose. A total of 56 children from 
Micronesia were adopted by Gajdusek. He put his adopted sons through schools, 
colleges, and a few through medical schools, using his Nobel award and his own 
salary for their support. In 1996, Gajdusek was accused of child molestation by one of 
his sons, at that time a 3rd year chemistry student at College Park, MD, who testified 
that, some 20 years earlier, Gajdusek abused him on his native island. Sentenced and 
jailed for one year, the 74 year old brilliant scientist left permanently the United 
States for Europe where he was received with open arms. 
He lived during summers in Amsterdam, and winters beyond the Arctic Circle in 
Tromse, Norway. He said that when it was dark during the 24-hour days, he could do 
more writing. In addition to more than 600 refereed papers, he wrote his diaries and 
donated the hard-bound mimeographed volumes to his close friends and a few 
libraries. He died in Tromse on December 12, 2008. 
 
 
1. Gajdusek,D.C. 1977. Unconventional viruses and the origin and disappearance of 
kuru. Science 197, 943-960. 
 
2. Gajdusek, D.C.1985. Subacute spongiform virus encepholopaties caused by 
unconventional viruses. In: Subviral pathogens of plants and animals: viroids and 
prions. K. Maramorosch and J. J. McKelvey, Jr.,eds. Academic Press, New York: 
483-544. 
 
3. Prusiner, S. B. 1982.  Novel proteinaceus infectious particles cause scrapie. 
Science 216, 136-144. 
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Cardiovascular disease (CVD) in women is the most common cause of death and in 
2009 accounted for one third of all deaths.  The purpose of this paper is to present what 
conditions during pregnancy and during the pre-menopause period lead to a greater risk 
of CVD. The early recognition and the application of interventions may decrease this 
risk. To emphasize this point we have taken a “Life Events-Course Perspective”. 
Current data suggests that genetic predisposition to disease in conjunction with 
behavior and environmental factors during fetal life is related to permanent changes in 
fetal-placental-maternal physiology and function, resulting in fetal programming 
characterizing the phenotype of the child which may persist into adulthood. 
Longitudinal studies have identified biological, behavioral and environmental factors 
related to childhood diseases such as hypertension, insulin resistance and mental health 
disorders. Gender differences have been identified and animal studies have suggested 
that estrogens in women are protective and when the risk of CVD in men is considered, 
the risk in women is delayed by 10 years. Thus, a normal pregnancy may be protective 
and reduce the risk of CVD in women. However, hypertension developing in women 
before or during pregnancy is a significant risk factor for women and diabetes further 
increases this risk of CVD, as does smoking. It is very clear that an “intervention action 
plan” must be developed. It is the current opinion of the authors that this action plan 
must be implemented early in life to decrease the risk for the development of CVS in 
women.   
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Vitamin D regulates placental development and function. It is a potent regulator of 
the immune system-stimulating antimicrobial responses while suppressing 
inflammation. Its deficiency has been linked to increased risk of serious chronic and 
inflammatory diseases. Vitamin D deficiency during pregnancy increases 
susceptibility to infection and inflammation, leading, in turn, to outcome like 
preterm birth or preeclampsia. Pregnant women with darker skin pigmentation are 
more likely to be vitamin D deficient, particularly when living in regions with low 
exposure to sunlight. It is possible that during pregnancy, a primary non-infectious 
inflammatory process is activated by vitamin D deficiency. Combined assessment of 
vitamin D deficiency and inflammatory markers in early pregnancy or during 
different stages of pregnancy may facilitate the recognition of the risk of 
complications.  
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Aim: To assess the use of vitamin, mineral and iron supplements during pregnancy in 
Zagreb and Novi Sad. Methods: The study was conducted by use of a structured 
standardized questionnaire consisting of two parts, i.e. data obtained by maternal 
interview and hospital records. It is designed as a cross-sectional study in two 
countries (Croatia and Serbia). The study included 893 pregnant women from Zagreb 
and 6099 pregnant women from Novi Sad. Results: In Zagreb, pregnant women 
reported highest utilization of vitamin-mineral supplements (n=508; 56.9%), whereas 
in Novi Sad these supplements ranked third (n=408; 20.3%), following tocolytics and 
iron supplements. There was no statistically significant difference in the prevalence of 
congenital malformations between neonates at in utero exposure to vitamins, minerals 
and iron supplements and those without such exposure in either Zagreb or Novi Sad 
arm, with the exception of iron and calcium supplementation in the Zagreb arm. 
Conclusions: In spite of certain study limitations, the results obtained pointed to the 
unreasonable and potentially harmful use of these supplements in pregnant women 
from Zagreb.  
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Pentraxins are a superfamily of proteins that are phylogenetically highly conserved in 
evolution. Based on the primary structure of subunits, pentraxins are divided into short 
and long pentraxins. C-reactive protein and serum amyloid P component are classic short 
pentraxins. The prototype of the long pentraxin family is pentraxin 3 (PTX3) which is 
rapidly produced and released by several cell types upon activation, in particular, by 
macrophages, dendritic cells, fibroblasts, and endothelial cells in response to 
proinflammatory signals. In addition, PTX3 is expressed in amniotic epithelium, 
chorionic mesoderm, trophoblast terminal villi, and perivascular stroma of placentas. The 
purpose of this study was to evaluate amniotic fluid concentration of PTX3 in patients 
with preterm premature rupture of the membranes and to determine whether amniotic 
fluid PTX3 concentrations are of value in the identification of patients with subclinical 
histological chorioamnionitis. Forty pregnant women with PPROM between 24 and 36 
gestation weeks without (n = 21) and with (n = 19) histological chorioamnionitis 
(PPROM group) and 42 women between 16 and 20 gestational weeks (mid-trimester 
group) were included in the study. We compared amniotic fluid PTX3 levels in the 
PPROM group with versus without histological chorioamnionitis, and between the 
PPROM and the mid-trimester groups. Patients with subclinical histological 
chorioamnionitis had a significantly higher median amniotic fluid PTX3 concentration 
than patients without the histological signs of chorioamnionitis (3.69 ng/mL, 0.51 – 106.8 
versus 0.8 ng/mL, 0.36 – 121.0; p = 0.015). Patients in the PPROM group reached a 
significantly higher median amniotic fluid concentration of PTX3 compared with those in 
the mid-trimester group (1.0 ng/mL, 0.36 – 121.0 versus 0.67 ng/mL, 0.4 – 2.8; p = 
0.007). Subclinical histological chorioamnionitis is associated with a significant increase 
of amniotic fluid PTX3 levels.  
This work was supported by a grant from Czech Science Foundation (No. 304-09-0494). 
 
Kacerovsky M, Tosner J, Drahosova M, Hornychova H, Andrys C. Pentraxin 3 in amniotic fluid as 
a marker of intra-amniotic inflammation in women with preterm premature rupture of membranes. 
Int J Gyneacol Obstet, 2010.–108, N3.– P. 203-206 
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Impaired bone homeostasis contributes to development of osteopenia, osteolysis and joint 
erosions during the rheumatoid arthritis (RA). Bone morphogenetic proteins (BMP) are 
crucially important regulators of osteogenesis. Activation of specific BMP receptors 
(BMPR) leads to activation of the major BMP signaling pathway, namely intracellular 
Smad proteins, as well as other, Smad-independent, pathways. Using in vitro tissue 
culture approaches we show that activation of NF-κB pathway with proinflammatory 
cytokines IL-1β and TNFα inhibits osteogenic differentiation of pluripotent mesenchymal 
precursor cells through Smad7-independent inhibition of Smad1/5 transcriptional 
activity. Immunoblot and EMSA experiments show that neither Smad1/5 
phosphorylation by BMPR-Is, nor direct Smad1/5 binding to DNA into BMP target genes 
promoters are affected by the activation of NF-κB pathway with TNFα, or by the 
overexpression of NF-κB signaling components. Nevertheless, Smad1/5 transactivation 
and, consequently, transcription of BMP target genes is greatly reduced upon activation 
of NF-κB signaling. Neither ectopic expression of Smad1/5, nor CBP/p300 can rescue 
the negative effect of NF-κB pathway activation. We used Real time PCR to analyse 
BMP and TNFα target genes mRNA induction in the presence of protein synthesis 
cycloheximide and found that negative effect of NF-κB activation requires new protein 
synthesis due to the induction of BMP signaling inhibitor expression. Futhermore, we 
found two distinct TNFα target genes that are novel potent inhibitors of BMP signaling. 
One of them, TWIST1 is a transcriptional target of NF-κB and has been implicated into 
repression of RUNX2 driven osteogenesis. Another one, KLF10/TIEG is induced by 
TNFα in NF-κB-independent manner. shRNA-mediated knockdown of the expression of 
each of these BMP signalling repressors results in partial rescue of BMP-Smad-driven 
transcription from inhibition by TNFα. We generated crosses of BMP reporter mice with 
p65/RelA knockout mice and found that NF-κB (most likely, via TWIST1) controls the 
intensity and the duration of BMP signals in vivo already during the embryogenesis. 
Thus, our data demonstrate TIEG1 and TWIST1 as transcriptional repressors of BMP-
Smad signalling and as the central candidates responsible for proinflammatory control of 
osteogenic program possibly also involved in the development of osteolysis and joint 
erosions during the RA.   
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Aim: Oxidative stress plays a role in the pathogenesis of ureteral obstruction. Methods: 
We studied parameters of oxidative status, levels of advanced glycation end products 
(AGEs), and contralateral (CL) kidney function in the rat model of unilateral ureteral 
obstruction (UUO). The effects of Phlogenzym (12 mg/d orally); losartan (20mg/l in 
drinking water), and their combination was studied. Results: In placebo-administered 
UUO rats AGEs and malondialdehyde levels were higher than in the sham operated 
controls. Function of the CL kidney was slightly impaired, its collagen content and 
protein/deoxyribonucleic acid ratio (P/DNA) in the glomeruli increased. All treatments 
prevented the rise in collagen content, P/DNA ratio, and improved CL kidney function. 
Phlogenzym ameliorated lipid peroxidation and AGE levels. Conclusions: In the model 
of UUO systemically increased oxidative stress may play a role in development of 
tubulointerstitial fibrosis and in the functional impairment of the CL kidney. Suppression 
of the oxidative stress and blockade of angiotensin-1 receptors might mitigate the 
progression of obstructive uropathy. 
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Gangliosides are characteristic extracellular-facing plasma membrane determinants in 
vertebrate brain. The four major gangliosides (GM1, GD1a, GD1b and GT1b) dominate 
among more than one hundred glycolipid structures in nervous tissue. During brain 
development the expression of simple gangliosides shifts toward more complex ones, 
accompanied by a multiple increase in their total amount. The shift is precisely regulated 
and some specific structures represent well established neurodevelopmental milestones.  
From the evolutionary perspective, the ganglioside content in fish and amphibian brain is 
significantly lower than in mammalian brain, but the general variability is greater. More-
polar structures, abundant in Antarctic fishes, are rare in higher vertebrates or expressed 
only in a narrow developmental frame. Reptiles, birds and mammals share identical 
common structures expressed in similar patterns with minor interspecies differences. On 
the contrary, fish and amphibian brains show significant interspecies differences in 
amount, structure and expression patterns.  
The initial assumption of evolutionary studies was that the variations in lipid content, 
particularly the glycolipid content, during temperature adaptations in ectothermic and 
hibernating heterothermic animals, represent an efficient molecular mechanism of the 
membrane function preservation. Studies of ordered lipid domains in the last decade 
verified the ganglioside-mediated regulation of membrane proteins (receptor kinases, 
neurotransmitter receptors and ion channels) as well as receptor-ligand interaction 
important for cell signaling.  
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Modulation of the expression and activity of plasma membrane ion channels is one of the 
mechanisms how immune cell can regulate their intracellular Ca2+ signaling pathways 
required for proliferation and/or differentiation. Dendritic cells (DCs) function as 
professional antigen presenting cells and participate in the initiation of adaptive immune 
response. Human monocyte-derived DCs have two developmental phenotypes: immature 
DCs (IDCs) take up and process foreign antigens, while mature DCs are able to trigger T 
cells in the lymph nodes. Our study aimed at the identification and characterization of ion 
channels expressed during the course of human DC differentiation. 
Human myeloid DCs were generated from monocytes isolated from peripheral blood 
mononuclear cells by positive selection with anti-CD14-coated magnetic beads. To 
generate IDCs cells were cultured in the presence of IL-4 and GM-CSF.  Maturation of 
IDCs into MDCs was induced by an inflammatory cocktail containing TNF-α, IL-1β, IL-
6, and GM-CSF. Ion currents of IDCs and MDCs were recorded using the whole-cell 
patch-clamp technique. The biophysical, pharmacological and molecular biological 
properties of the channels were determined and used for the classification of the 
expressed channels. 
We report here the first time that IDCs express voltage-gated Na+ channels in their 
plasma membrane. The parameters characterizing voltage-dependent gating (activation 
and inactivation) and the TTX sensitivity of the current and PCR-based cloning revealed 
the presence of Nav1.7 channels in human IDCs. Transition from the immature to the 
mature state, however, was accompanied by a down-regulation of Nav1.7 expression 
concomitant with the expression of a K+ current having biophysical characteristic of a 
voltage-gated Kv1.3 current. The expression of Kv1.3 channels by MDCs was confirmed 
by high affinity block of the current by margatoxin, a selective inhibitor of Kv1.3 
channels, and by PCR-based cloning. The presence of Kv1.3 channels seems to be 
common for immune cells; hence, selective Kv1.3 blockers may emerge as candidates for 
inhibiting various functions of mature DCs that involve their migratory, cytokine 
secreting and T-cell activating potential. 
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My own concepts of the Synthetic Biology and Gene Therapy evolved gradually between 
the 1940’s, 1970’s and beyond. It all started when I was born in 1921 in Lwow, and was 
influenced by my teachers and the pioneering biological research of Professor Rudolf 
Weigl, also being trained as a chemical engineer at the Politechnika Lwowska. It would 
be difficult for me to recall all the lectures and seminars where I have introduced, 
described and used my novel term of Synthetic Biology, but some examples were found 
and preserved by various reviewers and also by the Editors of Wikipedia, since under the 
entry, “Synthetic Biology” it says: 
“In 1974, the Polish geneticist Waclaw Szybalski introduced the term "synthetic 
biology"[1], writing: Let me now comment on the question "what next". Up to now we 
are working on the descriptive phase of molecular biology. ... But the real challenge will 
start when we enter the synthetic biology phase of research in our field. We will then 
devise new control elements and add these new modules to the existing genomes or build 
up wholly new genomes. This would be a field with the unlimited expansion potential and 
hardly any limitations to building "new better control circuits" and finally other 
"synthetic" organisms, like a "new better mouse". I am not concerned that we will run out 
of exciting and novel ideas, in the synthetic biology, in general. When in 1978 the Nobel 
Prize in Physiology or Medicine was awarded to Arber, Nathans and Smith for the 
discovery of restriction enzymes, Waclaw Szybalski wrote in an editorial comment in the 
journal Gene: The work on restriction nucleases not only permits us easily to construct 
recombinant DNA molecules and to analyze individual genes, but also has led us into the 
new era of synthetic biology where not only existing genes are described and analyzed 
but also new gene arrangements can be constructed and evaluate[2].  
If we use 1974 as the start point, the Synthetic Biology is presently 35 years old”. 
Let me list here several examples of experiments performed by myself or in my 
laboratory, which at that time, I thought, would represent various modes of chemical 
organic or enzymatic DNA synthesis DNA in association with the living organisms. 
These included various method of transferring biologically active DNA, necessary 
biological and other assays, physical mapping and sequencing of DNA, cutting and 
splicing of genomes, and modifying or creating of novel organisms. 
1) We chemically modified DNA by replacing thymine with halogenated analogues, and 
we were first to prove that such DNA retains its biological transforming activity. That 
convinced me that DNA could be chemically manipulated, even by an organic 
chemist, like myself, or by my collaborators, late Stefan Zamenhof. Zofia Opara-
Kubinska and Erela Elizur. 
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2) Another chemical manipulation, the total enzymatic synthesis of DNA, was first 
described by the late A. Kornberg, but there was no proof that synthesis in highly 
purified system leads to a ‘life-like’ DNA. Thus, in cooperation with the late Rose 
Litman and using a more crude enzymatic system, but in conjunction with very 
sophisticated, at that time, method of quantitative separation of the template from the 
newly synthesizes DNA, I and the late Zofia Opara Kubinska we were able to prove 
that DNA synthesized by Rose was biologically alive, as determined by the 
transforming activity. Probably, it was the first proof for the synthesis of life in the 
test tube.  
3) To be able to test DNA not only in bacteria, but also in eukaryotic systems, we have 
designed a very novel selective system, named by my wife HAT, which for the first 
time permitted us to transfect the human cells with purified DNA. To do that, we 
produced deletions in the HPRT gene, which corresponded to the “synthetic Lesch-
Nyhan syndrome”, which incidentally, was not discovered until 1964. Transfection 
with the HPRT+   DNA yielded the HPRT+  transfectants, while this operation 
corresponded to the in vitro gene therapy of the cells with a “synthetic” Lesch-Nyhan 
syndrome.  
(4) Ultimately, our HAT section procedure has permitted us also to develop hybridoma 
cells by the fusion of my own HPRT+ epithelial cells and our laboratory bone marrow 
D98/AH cell line that was HPRT-. Ultimately, that led others to the new field of 
monoclonal antibodies (mAbs), that could be also considered as a synthetic product. 
(5) The restriction endonucleases provide a powerful tool to engineer DNA in vitro 
leading to assembly various combination of genes.  My laboratory was quite active in 
this area, also inventing new tricks and creating novel ‘synthetic’ enzyme activities.  
(6) That led to a new huge field of recombinant DNA (reDNA) and new kinds of the 
biotechnological industries. 
(7) Among most important of our tools for physical mapping the synthetic genomes were 
electron microscopy of DNA heteroduplexes supplanted later by the outright DNA 
sequencing. 
 
As an aside, we attempted in 1962 to synthesize new kind of ‘viruses’, which mimic the 
properties of the scrappie-like viruses that are an example of the infectious protein. As 
model, we used termination (t)/anti-termination (nut) elements of our DNA phage 
lambda and the N protein. 
The field of the Synthetic Biology (SB) is now well established with various attempts to 
produce synthetic organisms almost totally from scratch, whereas Gene Therapy has still 
long way to go as to become a standard clinical procedure. 
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Applications of nanotechnology for treatment, diagnosis, monitoring, and control of 
biological systems has recently been referred to as “nanomedicine” by the National 
Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, 
therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These 
involve the identification of precise targets (cells and receptors) related to specific 
clinical conditions and choice of the appropriate nanocarriers to achieve the required 
responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, 
endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are among 
the key targets. Today, nanotechnology and nanoscience approaches to particle design 
and formulation are beginning to expand the market, particularly for the anticancer drugs, 
and are forming the basis for a highly profitable niche within the industry, but some 
predicted benefits are hyped. This lecture will highlight rational approaches in design and 
surface engineering of nanoscale vehicles and multifunctional entities for site-specific 
drug delivery and medical imaging after parenteral administration. Potential pitfalls or 
side effects (e.g., cytotoxicity and adverse immune reactions) associated with 
nanoparticles and their constituents will be discussed at the molecular level. 
 
Parhamifar, L. et al., (2010) Soft Mat. (in press); Moghimi, S.M. et al., (2010) J. Control. Rel. (in 
press); Moghimi, S.M. and Andresen, T.L. (2009) Mol. Immunol., 46: 1571–1572; Hamad, I. et al., 
(2008) Mol. Immunol., 46: 225–232;  Hamad, I and Moghimi, S.M. (2008) Exp. Opin. Drug Deliv., 
5: 205−219; Moghimi, S.M. and Moghimi, M. (2008) BBA-Biomembranes 1778: 51–55; 
Mukhopadhyay, R. et al., (2007) J. Am. Chem. Soc., 129: 13390–13391; Moghimi, S.M. et al., 
(2006) FASEB J., 20: 2591–2593; Moghimi, S.M. and Kissel, T. (2006) Adv. Drug Deliv. Rev., 58: 
1451–1455; Moghimi, S. M. (2006) Biomaterials 27: 136–144; Moghimi, S. M. et al., (2005) Mol. 
Ther., 11: 990–995; Symonds, P. et al., (2005) FEBS Lett., 579: 6191–6198; Moghimi, S.M. et al., 
(2005) FASEB J., 19: 311–330; Moghimi, S.M. et al., (2004) Science 303: 626–627; Moghimi, 
S.M. and Szebeni, J., (2003) Prog. Lipid Res., 42: 463–478; Moghimi, S.M. et al., (2001) 
Pharmacol. Rev, 53: 283–318. 
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Currently, industrial microbial producers of pharmaceutically important metabolites and 
heterologous proteins are isolated by methods of metabolic engineering. This will be 
illustrated by examples based on works carried out in Institute of Cell Biology. Thus, 
efficient producers of riboflavin (vitamin B2) and flavin nucleotides FMN and FAD have 
been constructed based on metabolically engineered yeast Candida flareri (Candida 
famata). The stable riboflavin overproducers were constructed by means of amplification 
of the gene encoding the positive regulator of riboflavin synthesis SEF1, structural genes 
of riboflavin biosynthesis pathway RIB1 and RIB7 and gene of purine nucleotide 
interconversion IMH3 into selected earlier C. flareri flavinogenic strains AF4. 
Overproducers of FMN and FAD de novo have been isolated for the first time by 
overexpression of genes FMN1 and FAD1 coding for riboflavin kinase and FAD 
synthetase, respectively, in the mentioned riboflavin producer C. flareri AF4. The 
medium composition and cultivation conditions were optimized for maximal 
accumulation of riboflavin, FMN and FAD. Microbial producers of anticancer enzyme 
arginine deiminase (ADI) from pathogenic bacterium Mycoplasma hominis have been 
constructed in Escherichia coli. To construct efficient producer of ADI, the 
corresponding gene was isolated from total DNA of M. hominis. The codon optimized 
gene was expressed in Escherichia coli cells. ADI expression level consisted of at least 
25% of the total bacterial proteins. The homogenous recombinant ADI with specific 
activity of 18 U/mg protein were obtained. Besides, the producers of human arginase 
(hARG1) have been constructed in the methylotrophic yeast Hansenula polymorpha. For 
the first time, overproduction and efficient secretion of catalytically active hARG1 were 
achieved in yeasts. Optimization of fermentation protocols and development of simple 
purification procedure for hARG1 were carried out. As anticancer enzymotherapy based 
on arginine deprivation is currently been vigorously developed, we expect the growing 
demand in preparations of recombinant arginine-degrading enzymes in near future, both 
for laboratory and clinical studies. In parallel, the work is in progress on the design of 
novel efficient combined therapies that utilize recombinant hARG1 on different tumor 
models.
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Novel functionalized nanocomposites (NC) were developed as a result of tight 
collaboration between the Department of Organic Chemistry at LNPU and the 
Department of Regulation of Cell Proliferation and Apoptosis at the ICB. In order to 
create the basic platform for these NC, the polymeric surface-active oligoelectrolytes 
were designed and synthesized [1]. The developed technology permits to control: 1) the 
quality and quantity of structural blocks of the NC, and the unimodality of their size (1.5-
6.0 kDa); 2) branching of the polymer chain at specific sites (if necessary); 3) providing 
the polymer with specific chemical groups (hydroxyl, carboxyl, amino, aldehyde, epoxy, 
others); 4) covalent conjugation of specific bio-targeting molecules via these groups. The 
following molecules were used as bioactive element of the developed NC: a) specific 
anticancer drugs, antibiotics, alkaloids; b) DNA and siRNA; c) immunoglobulins and 
lectins; d) low molecular compounds (lipids, amino acids); e) polyethylene glycol. To 
make these NC detectable and measurable, fluorescent and other dyes [2], as well as 
super-paramagnetic core were utilized. Biocompatible NC possessing low toxicity 
towards mammalian cells in vitro and in vivo (experimental mice) were selected. These 
NC were applied in the form of micelle materials or nanoparticles for delivery of: 1) 
drugs (ex. doxorubicine and levomycetin) during chemotherapy in vitro and in vivo; 2) 
DNA (transfection of mammalian, yeast and bacterial cells) and siRNA (blocking gene 
expression in vivo); 3) protein antigens at animal immunization [3]. Novel technologies 
were also developed for detecting and measuring apoptotic (dying) mammalian cells via 
recognizing specific cell surface glycoprotein(s) by means of specific lectin conjugated 
with the NC used in the form of nanoparticles [4]. Similar NC were applied for targeted 
action towards apoptotic human cells (cell isolation and destruction).  Apoptosis supports 
cell homeostasis in norm and is responsible for tissue damage in pathology. It is also 
involved in chemotherapy and radiotherapy. Thus, the developed nanotechnologies can 
be important in diagnostics and monitoring of treatment.  
1. Zaichenko A., Mitina N., Shevchuk O., et al. Pure Appl. Chem., 2008, V.80, N11, P. 2309-2326.  
2. Bilyy R., Podhorodecki A., Nyk M., et al: Low-dimensional Systems and Nanostructures, 2008. 
V.40, P. 2096-2099.  
3. Kit Y., Bilyy R., Stoika R., Mitina N., Zaichenko A. In: Biocompatible Nanomaterials: 
Synthesis, Characterization and Applications. Nova Sci. Publ., Inc., Hauppauge – NY. 2010.  
4. Bilyy R., Tomyn A., Kit Yu., et al. Mat. Sci. and Engin.  Techn., 2009. V.40, N4, P. 234-237.  
These studies were partly supported by STCU grants #1930, #4140, #4953. 
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Rapidly growing interest in magnetic nano- and microparticles is determined by the 
progress in nanotechnology in medical diagnostics and treatment including magnetic 
targeting, drug delivery and hyperthermia. For example, superparamagnetic iron oxide 
nanoparticles (~ 10-30 nm in size) were developed to label the transplanted cells in 
order to non-invasively visualize their survival, migration, homing and fate in 
magnetic resonance imaging (MRI) which is of key importance for success of cell 
therapy and regenerative medicine. The efficacy of iron oxide nanoparticles depends 
mainly on their physicochemical properties, particularly on their size and surface 
chemistry. Examples of successful surface modification of iron particles for labeling 
of various types of cells will be given.  On the other side, magnetic microspheres (~ 1-
3 µm in size) play important role in immobilization of proteins, peptides and 
enzymes, bioseparation applications, biosensors and so on. In the design of magnetic 
microspheres suitable for the detection of circulating tumor cells in peripheral blood, 
we have developed magnetic poly(2-hydroxyethyl methacrylate)-based microspheres 
containing carboxyl groups suitable for subsequent attachment of biomolecules. 
Requirements laid on such microspheres include also complete encapsulation of iron 
oxide to avoid its contact with the environment, high iron oxide content to get high 
magnetization, no particle aggregation in physiological media, monodisperse size to 
have uniform physicochemical properties, low non-specific adsorption of proteins and 
low autofluorescence. Such particles will be described in more detail.  
 
Support of Ministry of Education, Youth and Sports of the Czech Republic (No. 2B06053) 
is acknowledged.  
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The aim of present research was investigation of anticancer activity of 4-
azolidinone-3-carboxylic acids derivatives, and studies of structure-activity 
relationships (SAR) aspects. Methods: organic synthesis; spectral methods; 
anticancer screening was performed according to the US NCI protocol 
(Developmental Therapeutic Program). Results. The data of new 4-thiazolidinone-
3-alkanecarboxylic acids derivatives in vitro anticancer activity were described. The 
most active compounds which belong to 5-arylidene-2,4-thia(imida)zolidinone-3-
alkanecarboxylic acids; 5-aryl(heteryl)idenerhoda-nine-3-cuccinic acids derivatives 
were selected. Determination of some SAR aspects which allowed to determine 
directions in lead-compounds structure optimization, as well as desirable molecular 
fragments for design of potential anticancer agents based on 4-azolidinone scaffold 
were performed. 5-Arylidenehydantoin-3-acetic acids amides were identified as a 
new class of significant selective antileukemic agents. Possible pharmacophore 
scaffold of 5-ylidenerhodanine-3-succinic acids derivatives was suggested. 
Conclusion. The series of active compounds with high anticancer activity and/or 
selectivity levels were selected. Some SAR aspects were determined and structure 
design directions were proposed. 
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The discovery of genes that are potential cancer-associated antigens and markers 
provides valuable insight into cancer biology and might lead to the development of 
more effective treatment strategies for combating this disease. In our study we applied 
several approaches for the identification novel tumor markers. Ovarian cancer is the 
most common gynecologic malignancy that usually becomes far advanced before it is 
diagnosed. So far, only few tumor-associated markers and antigens specific for ovarian 
cancer have been identified. MX35 antigen is one of them. MX35 specific Mabs 
developed against ovarian cancer showed homogeneous reactivity with approximately 
90% of human ovarian epithelial cancers and with a limited number of normal tissues 
by immunohistochemistry. Although mAb MX35 has been used in a number of clinical 
trials in ovarian cancer, the molecular identity of MX35 was unknown. I our study we 
have received strong evidence that antigen recognizes by mAb MX35 corresponds to 
the sodium-dependent phosphate transport protein 2b (NaPi2b). This conclusion is 
based on several lines of experimental evidence, including 1) the identification of 
SLC34A2, the gene coding for NaPi2b, by immunoscreening an ovarian cancer cell line 
cDNA expression library with mAb MX35; 2) mass spectrometry sequencing of 
peptides obtained from mAb MX35 affinity-purified antigen; 3) selective down-
regulation of SLC34A2 gene expression by RNA interference and the resulting loss of 
mAb MX35 binding to MX35-expressing cells; and 4) the demonstration of specific 
mAb MX35 reactivity with recombinant fusion proteins and with synthetic peptides of 
the putative largest extracellular loop of NaPi2b. We believe that membrane transporter 
molecules, such as NaPi2b, represent a new family of potential cell surface targets for 
the immunotherapy of cancer with monoclonal antibodies.  
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The adaptor/scaffold protein Ruk/CIN85 was implicated in carcinogenesis by 
influencing a number of processes such as cell adhesion, motility and apoptosis. 
Although Ruk/CIN85 appears to modulate tyrosine kinase receptors and PI3 kinase 
signalling, the exact molecular mechanisms by which Ruk/CIN85 affects 
carcinogenesis are largely unknown. Therefore, we investigated the oncogenic 
potential of Ruk/CIN85 by overexpressing the full-length isoform in weakly invasive 
MCF-7 breast adenocarcinoma cells. The Rukl/CIN85 overexpressing cells showed a 
slower growth rate, decreased cell adhesion, and an enhanced anchorage-independent 
growth in soft agar. Further, overexpression of Rukl/CIN85 also affected EGF-
dependent signalling: activation of both Akt and ERK1/2 was faster than in the 
control cells and both kinases remained in their active state for up to 30 min after EGF 
treatment. Transwell migration and wound healing assays revealed that Rukl/CIN85 
overexpressing cells possessed increased motility. The EGF-induced motility was 
attenuated in Rukl/CIN85-overexpressing cells but could be restored upon knock-
down of Rukl/CIN85 with specific shRNA. Together, these findings suggest that high 
levels of Rukl/CIN85 can modulate EGF-dependent signalling and contribute to the 
conversion of breast adenocarcinoma cells into a more malignant phenotype. 
 
 
